MedTrace Logo

Prospective G7 Dual Mobility Total Hip PMCF

NCT03308929 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-06-15

No results posted yet for this study

Summary

This is a prospective multi-center clinical evaluation following recipients of the G7 Dual Mobility hip device. The primary objective is to characterize survivorship of the G7 hip at five years post-index procedure. Secondary objectives include documentation of clinical outcomes, safety and radiographic data.

Conditions

  • Clinical Outcomes
  • Functional Outcomes
  • Radiological Outcomes
  • Survivorship
  • Safety

Interventions

DEVICE

G7 Dual Mobility hip

Total hip arthroplasty and implantation of the G7 device

Sponsors & Collaborators

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Hillary Overholser, MS · Zimmer Biomet

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2027-07-01
Completion
2029-02-28
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03308929 on ClinicalTrials.gov